研究单位：[1]Chengdu Kanghong Biotech Co., Ltd.[2]The General Hospital of the People's Liberation Army,Beijing,China[3]Beijing Friendship Hospital, Capital Medical University,Beijing,China[4]Peking Union Medical College Hospital,Beijing,China[5]Peking University First Hospital,Beijing,China[6]Peking University People's Hospital,Beijing,China[7]Peking University Third Hospital,Beijing,China[8]The Second Hospital of Jilin University,Changchun,China[9]The Second Xiangya Hospital of Central South University,Changsha,China[10]West China Hospital Sichuan University,Chengdu,China[11]Army Medical Center,Chongqing,China[12]The Second Hospital of Dalian Medical University,Dalian,China[13]Zhongshan Ophthalmic Center, Sun Yat-Sen University,Guangzhou,China[14]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,China[15]The 2nd Affiliated Hospital of Harbin Medical University,Harbin,China[16]The Jiangxi Provincial People's Hospital,Nanchang,China[17]Jiangsu Province Hospital,Nanjing,China[18]Nanjing First Hospital,Nanjing,China[19]The First Affiliated Hospital of Guangxi Medical University,Nanning,China[20]Beijing Tongren Hospital, Capital Medical University,Peking,China[21]Eye & Ent Hospital of Fudan University,Shanghai,China[22]Shanghai General Hospital,Shanghai,China[23]Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China[24]Zhongshan Hospital,Shanghai,China[25]The First Hospital of China Medical University,Shenyang,China[26]Tianjin Eye Hospital,Tianjing,China[27]Tianjin Medical University Eye Hospital School of Optometry & Eye Institute,Tianjin,China[28]The First Affiliated Hospital of Xinjiang Medical University,Urumqi,China[29]Eye Hospital,WMU Zhejiang Eye Hospital,Wenzhou,China[30]Wuhan General Hospital of Guangzhou Military Command,Wuhan,China[31]Wuxi No.2 People's Hospital,Wuxi,China[32]The First Affiliated Hospital of Xi'An,Xi'an,China
研究目的：
The purpose of this study is to verify the efficacy and safety of intravitreal injection of conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion (BRVO).
